Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved NOXAFIL (posaconazole) 100 mg delayed-release
tablets. NOXAFIL delayed-release tablets are a new formulation with a
loading dose of 300 mg (three 100 mg delayed-release tablets) twice
daily on the first day, followed by a once-daily maintenance dose of 300
mg (three 100 mg delayed-release tablets) starting on the second day of
therapy.
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 908-423-5042Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more